Proteomics Market

Proteomics Market Size:

The global proteomics market size reached US$ 36.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 126.2 Billion by 2032, exhibiting a growth rate (CAGR) of 14.4% during 2024-2032. The market is primarily driven by rapid technological advancements in mass spectrometry, increasing incidents of chronic diseases, and rapid shift towards personalized medicines. Moreover, increasing integration of machine learning (ML) and artificial intelligence (AI) are upgrading protein analysis and data interpretation.

Proteomics Market Analysis:

• Major Market Drivers: Some of the major market drivers of the proteomics market include rising prevalence of chronic diseases, escalating demand for personalized medicines, and advancements in bioinformatics and mass spectrometry. Innovations in protein analysis, coupled with investments in private and government sectors, further boost market growth. Moreover, extensive applications of proteomics in diagnostics and drug discovery improve its market prospect, encouraging active adoption and development in both research and clinical sectors.
• Key Market Trends: Some of the key trends include surge in multi-omics approaches, rapid incorporation of ML and AI, and collaborations between key companies and academic institutions. The soaring inclination towards targeted therapies and personalized medicine spurs innovations in proteomics market. In addition, the increasing emphasis on early detection of diseases and biomarker discovery, and proteomics applications expansion in drug development are critical trends shaping the proteomics market outlook.
• Geographical Trends: Proteomics market in North America is witnessing substantial growth, propelled by significant research funding and technological advancements. This region is closely followed by Europe, profiting from dynamic healthcare infrastructure and strategic collaborations. Asia Pacific is exhibiting rapid market expansion due to increasing healthcare requirements and elevated investments in biotechnology. Middle East and Africa, and Latin America are also gaining momentum in the global market, supported by enhancing research abilities and increasing focus on personalized healthcare, and thus in turn, driving the proteomics market growth.
• Competitive Landscape: Some of the major market players in the proteomics industry include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, among many others.
• Challenges and Opportunities: Major challenges in the global proteomics market include sophisticated data analysis, high costs of advanced technologies, and insufficient standardized protocols. However, these challenges pave numerous opportunities including development of advanced bioinformatics software and cost-efficient solutions. Escalated private fundings and government investments further boost growth. Moreover, the extensive utilization of proteomics in disease diagnostics and personalized medicine delivers substantial potential for market propulsion and improved healthcare outcomes. Partnerships across various sectors can efficiently mitigate challenges and uncover new proteomics market opportunities.
   

Proteomics Market Trends:

Technological Advancements in Mass Spectrometry

Advancements in mass spectrometry is significantly expanding the proteomics market as it has facilitated the precise protein identification and quantification in critical biological samples. New mass spectrometers offer improved resolution as well as sensitivity. Furthermore, innovations like data-dependent acquisition methods and high-resolution tandem have enhanced the instrument’s ability to analyze the post-translational modifications and protein interactions, positively influencing the proteomics market forecast. For instance, in May 2024, Waters Corporation released a new mass spectrometer ACQUITY QDa II Mass Detector that is portable and highly efficient in delivering high-quality, mass spectral data to chromatographic separations. It offers 20% enhancement in mass range and 70% reduction in energy consumption and heat output compared to similar instruments.

Integration of Machine Learning and Artificial Intelligence

Artificial intelligence (AI) and machine learning (ML) are rapidly being integrated into proteomics, which has facilitated its automation. As per proteomics market insights, such advanced technologies are substantially revolutionizing data interpretation and analysis, consequently boosting proteomics demand in certain sectors. Large-scale proteomic data can be handled using AI and ML, promoting more accurate and efficient identification of biomarkers and protein patterns. Additionally, these algorithms significantly enhance the predictability of proteomics studies in early disease detection, clinical diagnostics, personalized drugs, etc. For instance, in October 2023, Stanford University researchers integrated AI with proteomic profiling for analysis of eye fluid samples for eye aging and neurogenerative diseases. Using this technique, aptamer-based proteomic assay profiling of 5,953 proteins was carried out in samples from 120 individuals.

Rising Adoption of Personalized Medicine

One of the proteomics market dynamics is the expanding personalized medicine adoption. Personalized medicine is customized for individual patients based on their proteomic and genetic profiles. Consequently, proteomics becomes requisite for the development of this drug as it aids in identification of disease related protein biomarkers. This trend is propelling the development of targeted diagnostics and therapies, upgrading treatment outcomes and lowering side effects. For instance, China has planned to invest RMB 60 billion in precision medicine by 2030 under the plan 'Healthy China 2030.'

Proteomics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on analysis type, component type, technology, application, and end-user.

Breakup by Analysis Type:

• Structural Proteomics
• Functional Proteomics
• Protein Expression Proteomics
   

The report has provided a detailed breakup and analysis of the market based on the analysis type. This includes structural proteomics, functional proteomics, and protein expression proteomics.

Structural proteomics is concerned with detailed analysis of protein interactions, structures, and functions. This field is required for studying disease mechanism and drug development. Advanced instruments and techniques boost growth, facilitating high-resolution structural comprehensions. Leading research institutions and companies are globally investing in structural proteomics to develop innovative therapeutic solutions.

Functional proteomics emphasizes on recognizing protein interactions and functions within a biological context. This discipline leverages advanced techniques to examine the dynamics of protein modifications, activities, and networks. In the global proteomics market, functional proteomics plays a crucial role by spurring innovations in personalized medicine, drug discovery, and disease diagnostics. By offering discernments into protein pathways and mechanisms, it encourages the development of targeted therapies and biomarker identification, substantially improving the efficacy and accuracy of medical treatments.

Protein expression proteomics examines the qualitative and quantitative aspects of protein formation within cells. It includes high-throughput techniques to compare and profile protein expression levels across various treatments or conditions. In the global proteomics market outlook, this subfield is pivotal for comprehending disease mechanisms, identifying biomarkers, and innovating novel therapeutic strategies. The proficiency of monitoring protein expression changes in response to numerous stimuli facilitates the development of enhanced and effective personalized medical initiatives and early detection of diseases.

Breakup by Component Type:

• Core Proteomics Services
• Bioinformatics Software and Related Services
   

A detailed breakup and analysis of the market based on the component type have also been provided in the report. This includes core proteomics services, and bioinformatics software and related services.

Core proteomics services include the protein identification, quantification, and analysis by leveraging advanced techniques such as chromatography and mass spectrometry. These services permit researchers to interpret complex protein interactions and functions, streamlining discoveries in therapeutic targets, disease mechanisms, and biomarker identification. Specialization in data acquisition, interpretation, and sample preparation is crucial for accurate results.

Bioinformatics software and related services provide crucial tools for data visualization and analysis. These services feature algorithms for protein structural prediction, sequence alignment, and functional annotation. Incorporating bioinformatics with proteomics propels research by reconfiguring raw data into meaningful biological insights, endorsing advancements in drug development and personalized medicine. For instance, in October 2023, Ionpath, a high-definition spatial proteomics developer, launched user-friendly bioinformatics tools named MIBIplus and MIBIsight that offers controlled data interpretation by using mass spectrometry to study various proteins associated with immune-oncology.

Breakup by Technology:

• Spectroscopy
• Chromatography
• Electrophoresis
• Protein Microarrays
• X-Ray Crystallography
• Surface Plasmon Resonance
• Others
   

Protein microarrays represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the technology. This includes spectroscopy, chromatography, electrophoresis, protein microarrays, X-ray crystallography, surface plasmon resonance, and others. According to the report, protein microarrays represented the largest segment.

Protein microarrays demonstrate a high-throughput platform in proteomics market, allowing simultaneous analysis of numerous protein samples. By immobilizing proteins on solid surfaces, these arrays foster rapid quantification and detection, promoting therapeutic development, biomarker discovery and diagnostics within the global proteomics market. For instance, in February 2024, Infinity Bio launched new technology, based on MIPSA technology, that leverages protein microarray method to analyze antibody-antigen binding. Maryland-based PTX Capital and Blackbird BioVentures granted USD 4 million fund to Infinity for the development of this technology, allowing the production of large arrays of proteins or peptides in a highly programmed manner. It also aids in combining full-length proteins and peptides in a single reaction, which allows researchers to study antibodies interaction with the 3D structure of full proteins and collect information on the specific peptide sequences that function as antibody epitopes.

Breakup by Application:

• Protein Expression Profiling
• Proteome Mining
• Post-translational Modifications
   

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes protein expression profiling, proteome mining, and post-translational modifications.

Protein expression profiling is a pivotal technique permitting the quantification and identification of proteins within a specific biological sample. This process offers valuable analysis of disease mechanisms and cellular functions, promoting the development of personalized medicine and targeted therapeutics by locating specific protein markers associated with numerous conditions.

Proteome mining is an inclusive approach that encompasses the systematic assessment of the entire proteome to discover novel proteins and apprehend their functions. This method propels advancements in drug development and biomarker discovery, presenting an in-depth understanding of potential therapeutic targets and biological processes for numerous diseases.

Post-translational modification (PTM) analysis targets the chemical modifications post the synthesis of proteins. These modifications greatly influence protein stability, function, and interactions. In the global proteomics market, PTM analysis aids in elucidating complex regulatory mechanisms, promoting the development of innovative diagnostics and treatments.

Breakup by End-User:

• Clinical Diagnostic Laboratories
• Research Organizations (Drug Discovery)
• Others
   

Research organizations dominate the market 

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes clinical diagnostic laboratories, research organizations (drug discovery), and others. According to the report, research organizations represented the largest segment.

By utilizing proteomic data, research organizations uncover new drug targets, expound disease mechanisms, and boost the development of effective treatments, consequently spurring advancements in biotechnological and pharmaceutical sectors. For instance, in July 2024, Olink Holding AB, a leading proteomics company, launched its network of Olink Certified Service Providers that will represent service labs and contract research organization (CROs) worldwide.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest proteomics market share 

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market, holding the largest share of the proteomics market revenue.

The market in North America is undergoing notable growth, principally driven by significant investments in research and development, and upgraded healthcare infrastructure. Furthermore, the increasing incidents of chronic diseases and intensifying focus on personalized medicine is boosting the market growth. In additional, robust support by government and funding initiatives escalate the utilization of proteomics technology in academic and clinical research. For instance, in September 2023, Multiomics CRO Psomagen launched its Spatial Biology services for 10X Genomics Xenium in North America. Psomagen's Xenium Service integrates various omics platforms, including proteomics, genomics, and transcriptomics.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the proteomics industry include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The competitive landscape of the global proteomics market is represented by the presence of major companies that are actively competing to strengthen their market position through strategic collaborations and technological advancements. For instance, in April 2024, Biognosys and Alamar Biosciences announced that they have entered into a strategic partnership for joint scientific research in biofluid-based proteomics. This partnership brings together Biognosys' expertise in data independent acquisition mass spectrometry (DIA-MS) and Alamar's cutting-edge immunoassays. Market players are currently emphasizing on research and development investment and expansion of their product portfolios to lead this swiftly evolving sector. Acquisitions and mergers are also common, aimed at unifying resources and expertise. The market is currently experiencing intense competition, fueled by escalating demand for advanced diagnostic tools and precision medicine, mandating continuous innovation.

Proteomics Market News:

• In June 2024, Agilent Technologies Inc., introduced its new product Agilent ExD Cell available for the 6545XT AdvanceBio LC/Q-TOF, which is integrated with electron capture dissociation (ECD) that enhances protein and peptide characterization capabilities. It is particularly built for the study of large and highly charged proteins, isomeric residues, and fragile modifications.
• In October 2023, Thermo Fisher Scientific agreed to acquire Olink Holding for approximately USD 3.1 billion to expand its proteomics presence in the market. Olink offers proteomics-focused products and services that align with Thermo Fisher's mass spectrometry and life sciences platforms.

Proteomics Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the proteomics market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global proteomics market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the proteomics industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.